AstraZeneca raises 2022 guidance, names Demaré as non-exec c...
AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – have allowed the company t